more on VKTX Viking Therapeutics priced concurrent offerings of 7,857,143 shares at $35 each and $225M in convertible notes, with settlement scheduled for September 25, 2026. · Larger offerings: Viking increased both the stock offering and the note offering from their previously announced $200M sizes. · Note terms: The senior unsecured notes pay 2.00% annual interest and mature October 15, 2032. · Conversion price: The initial price is approximately $50.75 per share, about 45% abo
more on VKTX Viking Therapeutics priced concurrent offerings of 7,857,143 shares at $35 each and $225M in convertible notes, with settlement scheduled for September 25, 2026. • Larger offerings: Viking increased both the stock offering and the note offering from their previously announced $200M sizes. • Note